Short Interest in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Declines By 63.6%

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) saw a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 27,000 shares, a decrease of 63.6% from the July 30th total of 74,099 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 50,747 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on RADX shares. HC Wainwright started coverage on shares of Radiopharm Theranostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $11.00.

Institutional Trading of Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc bought a new stake in Radiopharm Theranostics during the fourth quarter worth about $54,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at approximately $76,000. Virtu Financial LLC acquired a new position in shares of Radiopharm Theranostics during the 4th quarter worth approximately $76,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Radiopharm Theranostics during the 4th quarter worth approximately $1,007,000.

Radiopharm Theranostics Stock Up 6.6%

Radiopharm Theranostics stock traded up $0.15 during mid-day trading on Friday, reaching $2.41. The company’s stock had a trading volume of 333,279 shares, compared to its average volume of 101,031. Radiopharm Theranostics has a 12 month low of $2.04 and a 12 month high of $16.25. The business’s 50 day simple moving average is $3.55 and its 200 day simple moving average is $4.24.

Radiopharm Theranostics (NASDAQ:RADX) last issued its quarterly earnings results on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The business had revenue of $0.49 million for the quarter. Research analysts anticipate that Radiopharm Theranostics will post -2.36 earnings per share for the current fiscal year.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.